Intravitreal ranibizumab and bevacizumab in combination with full-fluence verteporfin therapy and dexamethasone for exudative age-related macular degeneration

Ophthalmic Research

Volumn 45, Issue 3, 2011, Pages 129-134

  Forte, Raimondo ^a   Bonavolontà, Paola ^a   Benayoun, Yohan ^b   Adenis, Jean Paul ^b   Robert, Pierre Yves ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

Anti vascular endothelial growth factor antibody; Foveal thickness; Optical coherence tomography; Retreatment; Triple therapy

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; RANIBIZUMAB; VERTEPORFIN;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; EXUDATIVE MACULAR DEGENERATION; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; RETREATMENT; RETROSPECTIVE STUDY; TREATMENT DURATION; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; FOVEA CENTRALIS; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 77956598999     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000318877     Document Type: Article

References (39)

1. Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials -TAP report 2. Arch Ophthalmol 2001; 119: 198-207. (Pubitemid 32147926)
2. Kaiser PK, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report No 8. Graefes Arch Clin Exp Ophthalmol 2006; 44: 1132-1142. (Pubitemid 44269592)
3. Schmidt-Erfurth U, Laqua H, Schlötzer-Schrehard U, Viestenz A, Naumann GO: Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 2002; 120: 835-844. (Pubitemid 34620368)
4. Potter MJ, Szabo SM: Recurrence of choroidal neovascularisation after photodynamic therapy in patients with age-related macular degeneration. Br J Ophthalmol 2007; 91: 753-756. (Pubitemid 46846645)
5. Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE, Haynes LA, Lewis H, Miller JW, Monés JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Schachat AP, Schmidt-Erfurth U, Sickenburg M, Singerman LJ, Slakter JS, Strong A, Vannier S, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Verteporfin therapy for subfoveal choroidal neovascularization in agerelated macular degeneration: Three-year results of an open-label extension of 2 randomized clinical trials -TAP report No 5. Arch Ophthalmol 2002; 120: 1307-1314. (Pubitemid 36105436)
6. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431. (Pubitemid 44511557)
7. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444. (Pubitemid 44511558)
8. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ: Intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration. Ophthalmology 2006; 113: 363-372.
9. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS: Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twelveweek results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112: 1035-1047. (Pubitemid 40797459)
10. Rosenfeld PJ, Moshfeghi AA, Puliafito CA: Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 331-335. (Pubitemid 41073112)
11. Rosenfeld PJ: Intravitreal Avastin: The low cost alternative to Lucentis? Am J Ophthalmol 2006; 142: 141-143. (Pubitemid 43946805)
12. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD, Venkatraman AS: Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006; 113: 1-12.
13. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group: Pegaptanib for neovascular agerelated macular degeneration. N Engl J Med 2004; 351: 2805-2816.
14. Augustin AJ, Puls S, Offermann I: Triple therapy for choroidal neovascularization due to age-related macular degeneration: Verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007; 27: 133-140.
15. Bakri SJ, Couch SM, McCannel CA, Edwards AO: Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration. Retina 2009; 29: 573-578.
16. Lazic R, Gabric N: Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007; 245: 68-73. (Pubitemid 46766732)
17. Ahmadieh H, Taei R, Soheilian M, Riazi-Esfahani M, Karkhaneh R, Lashay A, Azarmina M, Dehghan MH, Moradian S: Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. BMC Ophthalmol 2007; 7: 10.
18. Yip PP, Woo CF, Tang HH, Ho CK: Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone. Br J Ophthalmol 2009; 93: 754-758.
19. Schmidt-Erfurth U, Scholtzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO: Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003; 44: 4473-4480. (Pubitemid 37186285)
20. Smith BT, Dhalla MS, Shah GK, et al: Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Retina 2008; 28: 675-681. (Pubitemid 351655118)
21. Lazic R, Gabric N: Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007; 114: 1179-1185. (Pubitemid 46829388)
22. Kaiser PK: Verteporfin therapy in combination with triamcinolone: Published studies investigating a potential synergistic effect. Curr Med Res Opin 2005; 21: 705-713. (Pubitemid 40695292)
23. Spaide RF, Sorenson J, Maranan L: Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005; 112: 301-304. (Pubitemid 40202568)
24. Rechtman E, Danis RP, Pratt LM, et al: Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 2004; 88: 344-347. (Pubitemid 38333711)
25. Spaide RF, Sorenson J, Maranan L: Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003; 110: 1517-1525. (Pubitemid 36962483)
26. Augustin AJ, Schmidt-Erfurth U: Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 141: 638-645.
27. Nicolo M, Ghiglione D, Lai S, et al: Occult with no classic choroidal neovascularization secondary to age-related macular degeneration treated by intravitreal triamcinolone and photodynamic therapy with verteporfin. Retina 2006; 26: 58-64. (Pubitemid 44391753)
28. Augustin AJ, Schmidt-Erfurth U: Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006; 113: 14-22. (Pubitemid 43021722)
29. Ruiz-Moreno JM, Montero JA, Barile S: Triamcinolone and PDT to treat exudative agerelated macular degeneration and submacular hemorrhage. Eur J Ophthalmol 2006; 16: 426-434. (Pubitemid 44049286)
30. http://www.qltinc.com/newsCenter/2009/ 090615.htm.
31. Fung AE, Lalwani GA, Rosenfeld PJ, et al: An optical coherence tomography guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 566-583.
32. Spaide R: Ranibizumab according to need: A treatment for age-related macular degeneration. Am J Ophthalmol 2007; 143: 679-680. (Pubitemid 46452536)
33. Maier MM, Feucht N, Fiore B, et al: Photodynamic therapy with verteporfin combined with intravitreal injection of ranibizumab for occult and classic CNV in AMD. Klin Monatsbl Augenheilkd 2009; 226: 496-502.
34. Azab M, Boyer DS, Bressler NM, et al: Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005; 123: 448-457. (Pubitemid 40489914)
35. Fong DS, Custis P, Howes J, Hsu JW: Intravitreal bevacizumab and ranibizumab for age-related macular degeneration: A multicenter, retrospective study. Ophthalmology 2010; 117: 298-302.
36. Fung AE, Rosenfeld PJ, Reichel E: The international intravitreal bevacizumab safety survey. Br J Ophthalmol 2006; 90: 1344-1349.
37. Heier JS, Boyer DS, Gulla TA, et al: Ranibizumab combined with verteporfin photodynamic therapy in neovascular age related macular degeneration: Year 1 results of the FOCUS Study. Arch Ophthalmol 2006; 124: 1932-1942.
38. Ferrara N, Damico L, Shams N, et al: Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006; 26: 859-870. (Pubitemid 44547437)
39. Boyer DS, Antoszyk AN, Awh CC, et al: Subgroup analysis of the MARINA Study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007; 114: 246-252. (Pubitemid 46172497)